Seminars in Oncology
Volume 33, Issue 1 , Pages 15-49 , February 2006

Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy

  • Frederick H. Hausheer

      Affiliations

    • BioNumerik Pharmaceuticals, Inc, San Antonio, TX
    • Corresponding Author InformationAddress correspondence to Frederick H. Hausheer, MD, FACP, BioNumerik Pharmaceuticals, Inc, Suite 1250, 8122 Datapoint Dr, San Antonio, TX 78229
    • ,
  • Richard L. Schilsky

      Affiliations

    • Biological Sciences Division, University of Chicago, Chicago, IL
    • ,
  • Stacey Bain

      Affiliations

    • BioNumerik Pharmaceuticals, Inc, San Antonio, TX
    • ,
  • Elmer J. Berghorn

      Affiliations

    • BioNumerik Pharmaceuticals, Inc, San Antonio, TX
    • ,
  • Frank Lieberman

      Affiliations

    • Department of Neurology, University of Pittsburgh, Pittsburgh, PA

References 

  1. Docetaxel . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 966
  2. Cisplatin . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 927
  3. Hilkens PH , van den Bent MJ . Chemotherapy-induced peripheral neuropathy . J Peripher Nerv Syst . 1997;2:350–361
  4. Rowinsky EK , Chaudhry V , Cornblath DR , et al.   Neurotoxicity of Taxol . JNCI Monogr . 1993;15:107–115
  5. Lipton RB , Apfel SC , Dutcher JP , et al.   Taxol produces a predominantly sensory neuropathy . Neurology . 1989;39:368–373
  6. Weiss RB . Miscellaneous toxicities . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. (ed 7). Cancer (Principles and Practice of Oncology) . vol 2: Philadelphia, PA: Lippincott; 2005;p. 2603–2607
  7. Paclitaxel . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 1096
  8. Oxaliplatin . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 1093
  9. McKeage MJ , Hsu T , Screnci D , et al.   Nucleolar damage correlates with neurotoxicity induced by different platinum drugs . Br J Cancer . 2001;85:1219–1225
  10. Thompson SW , Davis LE , Kornfeld M , et al.   Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies . Cancer . 1984;54:1269–1275
  11. Gregg RW , Molepo JM , Monpetit VJ , et al.   Cisplatin neurotoxicity (the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity) . J Clin Oncol . 1992;10:795–803
  12. Screnci D , Er HM , Hambley TW , et al.   Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin . Br J Cancer . 1997;76:502–510
  13. Verdu E , Vilches JJ , Rodriguez FJ , et al.   Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice . Muscle Nerve . 1999;22:329–340
  14. Gill JS , Windebank AJ . Cisplatin-induced apoptosis in rat root ganglion neurons is associated with attempted entry into the cell cycle . J Clin Invest . 1998;101:2842–2850
  15. Openshaw H , Beamon K , Synold TW , et al.   Neurophysiological study of peripheral neuropathy after high-dose paclitaxel . Clin Cancer Res . 2004;10:461–467
  16. New PZ , Jackson CE , Rinaldi D , et al.   Peripheral neuropathy secondary to docetaxel (Taxotere) . Neurology . 1996;46:108–111
  17. Quasthoff S , Hartung HP . Chemotherapy-induced peripheral neuropathy . J Neurol . 2002;249:9–17
  18. Peltier AC , Russell JW . Recent advances in drug-induced neuropathies . Curr Opin Neurol . 2002;15:633–638
  19. Hol EM , Bär PR . Cisplatin neuropathy . Neurology . 1995;45:596
  20. Müller LJ . Morphological and electrophysiological study of the effects of cisplain and ORG 2766 on rat spinal ganglion neurons . Cancer Res . 1990;50:2437–2442
  21. Sahenk Z , Barohn R , New P , et al.   Taxol neuropathy . Arch Neurol . 1994;51:726–729
  22. Barajon I , Bersani M , Quartu M , et al.   Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy . Exp Neurol . 1996;138:93–104
  23. Cavaletti G , Cavalletti E , Oggioni N , et al.   Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration . Neurotoxicology . 2000;21:389–393
  24. Cavaletti G , Tredici G , Braga M , et al.   Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol . Exp Neurol . 1995;133:64–72
  25. Cavaletti G , Tredici G , Marmiroli P , et al.   Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats . Acta Neuropathol (Berl) . 1992;84:364–371
  26. Holmes J , Stanko J , Varchenko M , et al.   Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model . Toxicol Sci . 1998;46:342–351
  27. Kociba RJ , Sleight SD . Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat . Cancer Chemother Rep . 1971;55:1–8
  28. Masurovsky EB , Peterson ER , Crain SM , et al.   Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol . Neuroscience . 1983;10:491–509
  29. Screnci D , McKeage MJ , Galettis P , et al.   Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs . Br J Cancer . 2000;82:966–972
  30. Krarup-Hansen A , Fugleholm K , Helweg-Larsen S , et al.   Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function . Brain . 1993;116:1017–1041
  31. Tulub AA , Stefanov VE . Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes . Int J Biol Macromol . 2001;28:191–198
  32. Hollenbeck PJ . Kinesin delivers (Identifying receptors for motor proteins) . J Cell Biol . 2001;152:F25–F28
  33. Heins S , Song YH , Wille H , et al.   Effect of MAP2, MAP2c, and tau on kinesin-dependent microtubule motility . J Cell Sci Suppl . 1991;14:121–124
  34. Pfister KK . Cytoplasmic dynein and microtubule transport in the axon (The action connection) . Mol Neurobiol . 1999;20:81–91
  35. Fazio R , Quattrini A , Bolognesi A , et al.   Docetaxel neuropathy (A distal axonopathy) . Acta Neuropathol (Berl) . 1999;98:651–653
  36. Xu Y , Sladky JT , Brown MJ . Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication . Neurology . 1989;39:1077–1083
  37. Peterson ER , Crain SM . Nerve growth factor attenuates neurotoxic effects of Taxol on spinal cord-ganglion explants from fetal mice . Science . 1982;217:377–379
  38. Hilkens PH , Verweij J , Vecht CJ , et al.   Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere) . Ann Oncol . 1997;8:187–190
  39. Argov Z , Mastaglia FL . Drug-induced peripheral neuropathies . Br Med J . 1979;1:663–666
  40. Cersosimo RJ . Cisplatin neurotoxicity . Cancer Treat Rev . 1989;16:195–211
  41. Screnci D , McKeage MJ . Platinum neurotoxicity (Clinical profiles, experimental models and neuroprotective approaches) . J Inorg Biochem . 1999;77:105–110
  42. Chaudhry V , Rowinsky EK , Sartorius SE , et al.   Peripheral neuropathy from taxol and cisplatin combination chemotherapy (clinical and electrophysiological studies) . Ann Neurol . 1994;35:304–311
  43. Corbo M , Balmaceda C . Peripheral neuropathy in cancer patients . Cancer Invest . 2001;19:369–382
  44. Cavaletti G , Fabbrica D , Minoia C , et al.   Carboplatin toxic effects on the peripheral nervous system of the rat . Ann Oncol . 1998;9:443–447
  45. Russell JW , Windebank AJ , McNiven MA , et al.   Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity . Brain Res . 1995;676:258–267
  46. Mandys V , Viale M , Vrana J , et al.   Neurotoxic effect of cisplatin and the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia . Anticancer Drugs . 1998;9:659–663
  47. Geldof AA . Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy . J Cancer Res Clin Oncol . 1995;121:657–660
  48. Jirsova K , Mandys V . Differences in the inhibition of neuritic outgrowth in organotypic cultures of rat foetal dorsal root ganglia treated with cisplatin and carboplatin (A comparative study) . Folia Histochem Cytobiol . 1997;35:215–219
  49. Konings PN , Makkink WK , van Delft AM , et al.   Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro . Brain Res . 1994;640:195–204
  50. Konings PN , Philipsen RL , van den Broek JH , et al.   Morphometric analysis of cisplatin-induced neurite outgrowth in N1E-115 neuroblastoma cells . Neurosci Lett . 1994;178:115–118
  51. Peyrot V , Briand C , Crevat A , et al.   Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro . Cancer Treat Rep . 1983;67:641–646
  52. Peyrot V , Briand C , Momburg R , et al.   In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II) . Biochem Pharmacol . 1986;35:371–375
  53. Goldstein LS , Yang Z . Microtubule-based transport systems in neurons (The roles of kinesins and dyneins) . Annu Rev Neurosci . 2000;23:39–71
  54. Tankanow RM . Docetaxel (A taxoid for the treatment of metastatic breast cancer) . Am J Health Syst Pharm . 1998;55:1777–1791
  55. Berger T , Malayeri R , Doppelbauer A , et al.   Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy . Eur J Cancer . 1997;33:1393–1399
  56. du Bois A , Schlaich M , Luck HJ , et al.   Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy . Support Care Cancer . 1999;7:354–361
  57. Chaudhry V , Chaudhry M , Crawford TO , et al.   Toxic neuropathy in patients with pre-existing neuropathy . Neurology . 2003;60:337–340
  58. Rowinsky EK , Cazenave LA , Donehower RC . Taxol (A novel investigational antimicrotubule agent) . J Natl Cancer Inst . 1990;82:1247–1259
  59. Katsumata N . Docetaxel (An alternative taxane in ovarian cancer) . Br J Cancer . 2003;89(suppl 3):S9–S15
  60. Mollman JE , Glover DJ , Hogan WM , et al.   Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721 . Cancer . 1988;61:2192–2195
  61. Anastasia P , Hay JW . Chemotherapy-induced neuropathy (Results of an oncology nurse survey) . Proc Am Soc Clin Oncol . 2002;21:200b; (abstr 2618)
  62. Cavaletti G , Bogliun G , Crespi V , et al.   Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer . J Clin Oncol . 1997;15:199–206
  63. Cavaletti G , Bogliun G , Marzorati L , et al.   Peripheral neurotoxicity of Taxol in patients previously treated with cisplatin . Cancer . 1995;75:1141–1150
  64. Forsyth PA , Balmaceda C , Peterson K , et al.   Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing . J Neurooncol . 1997;35:47–53
  65. van Gerven JM , Moll JW , van den Bent MJ , et al.   Paclitaxel (Taxol) induces cumulative mild neurotoxicity . Eur J Cancer . 1994;30A:1074–1077
  66. Rowinsky EK , Eisenhauer EA , Chaudhry V , et al.   Clinical toxicities encountered with paclitaxel (Taxol) . Semin Oncol . 1993;20(suppl 3):1–15
  67. Ostchega Y , Donohoe M , Fox N . High dose cisplatin-related peripheral neuropathy . Cancer Nurs . 1988;11:23–32
  68. Schaumburg HH , Spencer PS . Toxic neuropathies . Neurology . 1979;29:429–431
  69. Paraplatin [package insert] . Princeton, NJ: Bristol-Meyers Squibb Company; 2004;
  70. du Bois A , Luck HJ , Meier W , et al.   Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer (An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group) . Semin Oncol . 1997;24(suppl 15):S15-44–S15-52
  71. Ozols RF , Bundy BN , Greer BE , et al.   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer (a Gynecologic Oncology Group study) . J Clin Oncol . 2003;21:3194–3200
  72. Cornblath DR , Chaudhry V , Carter K , et al.   Total neuropathy score (Validation and reliability study) . Neurology . 1999;53:1660–1664
  73. Screnci D , McKeage MJ . Platinum neurotoxicity (Clinical profiles, experimental models and neuroprotective approaches) . J Inorg Biochem . 1999;77:105–110
  74. Petersen PM , Hansen SW . The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer . Ann Oncol . 1999;10:1475–1483
  75. Eloxatin [package insert] . New York, NY: Sanofi-Synthelabo Inc; 2002;
  76. Thalomide [revised package insert] . Warren, NJ: Calgene Corp; 1998;
  77. Hausheer F , Kochat H , Zhao A , et al.   BNP7787 (A novel neuroprotective agent in taxane and platinum regimens does not interfere with chemotherapeutic effects) . Proc Am Assoc Cancer Res . 2001;42:370; (abstr 1990)
  78. Hausheer F , Kochat H , Reddy D , et al.   BNP7787 (A Novel chemoprotecting agent for platinum and taxane toxicity) . Proc Am Assoc Cancer Res . 2000;41:769–770 (abstr 4890)
  79. Platinol-AQ [package insert] . Princeton, NJ: Bristol-Meyers Squibb Co; 1999;
  80. Taxol [package insert] . Princeton, NJ: Bristol-Meyers Squibb Co; 2003;
  81. Taxotere [package insert] . Bridgewater, NY: Aventis Pharmaceuticals, Inc; 2005;
  82. Vincristine sulfate injection [package insert] . Irvine, CA: GensiaSicor Pharmaceuticals; 1999;
  83. Velcade [package insert] . Cambridge, MA: Millennium Pharmaceuticals, Inc; 2005;
  84. Wasserheit C , Frazein A , Oratz R , et al.   Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer (Active regimen with limiting neurotoxicity) . J Clin Oncol . 1996;14:1993–1999
  85. Rosell R , Gatzemeier U , Betticher DC , et al.   Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer (A cooperative multinational trial) . Ann Oncol . 2002;13:1539–1549
  86. Connelly E , Markman M , Kennedy A , et al.   Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers (Unexpected incidence of neurotoxicity) . Gynecol Oncol . 1996;62:166–168
  87. Wul FL , Brites C , Quevedo S , et al.   Difference in the evaluation of symptoms between patients and their doctors in an oncologic hospital . Proc Am Soc Clin Oncol . 2002;21:264b; (abstr 2874)
  88. Hopwood P , Stephens RJ , Machin D . Approaches to the analysis of quality of life data (experiences gained from a Medical Research Council Lung Cancer Working Party Palliative Chemotherapy Trial) . Qual Life Res . 1994;3:339–352
  89. Slevin ML , Plant H , Lynch D , et al.   Who should measure quality of life, the doctor or the patient? . Br J Cancer . 1988;57:109–112
  90. Varricchio CG , Bass E , Novotny P , et al.   Common toxicity criteria versus symptom specific measures (How congruent are the data?) . Proc Am Soc Clin Oncol . 2002;21:270b; (abstr 2897)
  91. Savage C , Pater J , Tu D , et al.   He said/she said (How well do common toxicity criteria and quality of life agree on patient symptoms?) . Proc Am Soc Cln Oncol . 2002; (abstr 1540)
  92. Stephens RJ , Hopwood P , Girling DJ , et al.   Randomized trials with quality of life end points (Are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings?) . Qual Life Res . 1997;6:225–236
  93. Shimozuma K , Ohashi Y , Takeuchi A , et al.   Validation of the patient neurotoxicity questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial of breast cancer (N-SAS BC 02) . San Antonio Breast Cancer Symposium . 2004; San Antonio, TX, December (abstr 6037)
  94. Seidman AD , Berry D , Cirrincione C , et al.   CALGB 9840 (Phase III study of weekly paclitaxel via 1-hour (h) infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for T in HER2 normal MBC) . Proc Am Soc Clin Oncol . 2004;22:6s; (abstr 512)
  95. Sikov W , Akerley W , Strenger R , et al.   Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer . Proc Am Soc Clin Oncol . 1998;17:112a; (abstr 432)
  96. Seidman AD , Hudis CA , Albanel J , et al.   Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer . J Clin Oncol . 1998;16:3353–3361
  97. Perez EA , Voegel CL , Irwin DH , et al.   Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer . J Clin Oncol . 2001;19:4216–4223
  98. Fountzilas G , Tsavdaridis D , Kalogera-Fountzila A , et al.   Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer; a Hellenic Cooperative Oncology Group phase II study . Ann Oncol . 2001;12:1545–1551
  99. Burstein HJ , Manola J , Younger J , et al.   Docetaxel administered on a weekly basis for metastatic breast cancer . J Clin Oncol . 2000;18:1212–1219
  100. Akerley W , Herndon JE , Egorin MJ , et al.   CALGB 9731 (Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)) . Proc Am Soc Clin Oncol . 1999;18:462a; (abstr 1783)
  101. Akerley W , Herndon JE , Egorin MJ , et al.   Weekly, high-dose paclitaxel in advanced lung cancer carcinoma (A phase II study with pharmacokinetics by the Cancer and Leukemia Group B (CALGB)) . Cancer . 2003;97:2480–2486
  102. Akerley W , Glantz M , Choy H , et al.   Phase I trial of weekly paclitaxel in advanced lung cancer . J Clin Oncol . 1998;16:153–158
  103. Akerley W . Paclitaxel in advanced non-small cell lung cancer (An alternative high-dose weekly schedule) . Chest . 2000;117(suppl 1):152S–155S
  104. Fidias P , Supko JG , Martins R , et al.   A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer . Clin Cancer Res . 2001;7:3942–3949
  105. Klaassen U , Wilke H , Strumberg D , et al.   Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer . Eur J Cancer . 1996;32A:547–549
  106. Fornier M , Seidman AD , Esteva FJ , et al.   Weekly (W) herceptin (H) + 1 hour taxol (T) (phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer (MBC)) . Proc Am Soc Clin Oncol . 1999; (abstr 482)
  107. Seidman AD , Fornier MN , Esteva FJ , et al.   Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification . J Clin Oncol . 2001;19:2587–2595
  108. Breier S , Lebedinsky C , Pelayes L , et al.   Phase I/II weekly paclitaxel (P) 80 mg/m2 in pretreated patients (pts) with breast (BC) and ovarian cancer . Proc Am Soc Clin Oncol . 1997;16:163a; (abstr 568)
  109. Chang L , Hui L , Boros R , et al.   Phase I study of weekly one-hour paclitaxel treatment in advanced malignant diseases . Proc Am Soc Clin Oncol . 1997;16:232a; (abstr 817)
  110. Cisplatin . In: Physician’s Desk Reference . Montvale, NJ: Thompson PDR; 2003;p. 859
  111. Becouarn Y , Ychou M , Ducreux M , et al.   Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers . J Clin Oncol . 1998;16:2739–2744
  112. Grothey A . Oxaliplatin-safety profile (Neurotoxicity) . Semin Oncol . 2003;30(suppl 15):5–13
  113. Gilles-Amar V , Garcia ML , Sebille A , et al.   Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in metastatic colorectal cancer . Proc Am Soc Clin Oncol . 1999;18: (abstr 944)
  114. Maindrault-Goebel F , Louvet C , Andre T , et al.   Oxaliplatin added to the simplified bimonthly leucovorin and 5-Fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6) . Eur J Cancer . 1999;35:1338–1342
  115. Cassidy J , Misset JL . Oxaliplatin-related side effects (Characteristics and management) . Semin Oncol . 2002;29(suppl 15):11–20
  116. Armand JP , Boige V , Raymond E , et al.   Oxaliplatin in colorectal cancer (An overview) . Semin Oncol . 2000;27(suppl 10):96–104
  117. Cvitkovic E , Bekradda M . Oxaliplatin (A new therapeutic option in colorectal cancer) . Semin Oncol . 1999;26:647–662
  118. de Gramont A , Figer M , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  119. Falcone A , Masi G , Allegrini G , et al.   Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin (A pilot study in patients with metastatic colorectal cancer) . J Clin Oncol . 2002;20:4006–4014
  120. Gamelin E , Gamelin L , Bossi L , et al.   Clinical aspects and molecular basis of oxaliplatin neurotoxicity (Current management and development of preventive measures) . Semin Oncol . 2002;29(suppl 15):21–33
  121. Giacchetti S , Perpoint B , Zidani R . Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol . 2000;18:136–147
  122. Gilles-Amar V , Garcia ML , Sebille A . Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48h leucovorn and 5-fluorouracil regimens with mestatic colorectal cancer . Proc Am Soc Clin Oncol . 1999;18:246a; (abstr 944)
  123. Maindrault-Goebel F , de Gramont A , Louvet C , et al.   High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) . Eur J Cancer . 2001;37:1000–1005
  124. Maindrault-Goebel F , de Gramont A , Louvet C , et al.   Bi-monthly oxaliplatin with leucovorin and 5-fluorouracil in pretreated metastatic colorectal cancer (FOLFOX6) . Proc Am Soc Clin Oncol . 1998;17:273a; (abstr 1049)
  125. Maindrault-Goebel F , de Gramont A , Louvet C , et al.  Oncology Multidisciplinary Research Group (GERCOR)   Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer . Ann Oncol . 2000;11:1477–1483
  126. Jin M , Chen Q , Cheng FQ , et al.   Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC) . Proc Am Soc Clin Oncol . 2002;21:140a; (abstr 558)
  127. Ravaioli A , Marangolo M , Pasquini E , et al.   Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer . J Clin Oncol . 2002;20:2545–2550
  128. Schmoll HJ . The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer (Prospects and future directions) . Semin Oncol . 2002;29(suppl 15):34–39
  129. Topham C , Adam R . Oncosurgery (a new reality in metastatic colorectal carcinoma) . Semin Oncol . 2002;29(suppl 15):3–10
  130. Oxaliplatin . In: Physician’s Desk Reference . Montvale, NJ: Thompson PDR; 2003;p. 2999
  131. Grothey A , Schmoll HJ . New chemotherapy approaches in colorectal cancer . Curr Opin Oncol . 2001;13:275–286
  132. Louvet C , Andre T , Tigaud JM , et al.   Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients . J Clin Oncol . 2002;20:4543–4548
  133. Paclitaxel Drug Package Insert . Princeton, NJ: Bristol-Myers Squibb; 2003; March
  134. Rowinsky EK , Donehower RC . Paclitaxel (Taxol) . N Engl J Med . 1995;332:1004–1014
  135. Sikov W , Akerley W , Strenger R , et al.   Weekly high-dose paclitaxel demonstrates significant activity in advanced breast cancer . Proc Am Soc Clin Oncol . 1998;17:112; (abstr 432)
  136. Mielke S , Mross K , Gerds TA , et al.   Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h . Anticancer Drugs . 2003;14:785–792
  137. Cavaletti G , Bogliun G , Marzorati L , et al.   Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale . Neurology . 2003;61:1297–1300
  138. Abraxane [package insert] . Schaumburg, IL: American Pharmaceutical Partners, Inc; 2005;
  139. Skubitz KM , Verschraegen CF , Daud A , et al.   A phase I study of paclitaxel poliglumex (PPX) in combination with cisplatin (CIS) for patients (pts) with advanced cancer . J Clin Oncol . 2005;23(suppl 1):157s; (abstr 2089)
  140. ten Tije AJ , Verweij J , Loos WJ , et al.   Pharmacological effects of formulation vehicles (Implications for cancer chemotherapy) . Clin Pharmacokinet . 2003;42:665–685
  141. Henningsson A , Karlsson MO , Vigano L , et al.   Mechanism-based pharmacokinetic model for paclitaxel . J Clin Oncol . 2001;19:4065–4073
  142. Henningsson A , Sparreboom A , Sandstrom M , et al.   Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients . Eur J Cancer . 2003;39:1105–1114
  143. Sparreboom A , van Zuylen L , Brouwer E , et al.   Cremophor EL-mediated alteration of paclitaxel distribution in human blood (Clinical pharmacokinetic implications) . Cancer Res . 1999;59:1454–1457
  144. Sparreboom A , Loos WJ , Verweij J , et al.   Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay . Anal Biochem . 1998;255:171–175
  145. MacNeil JS . ABI 007 . Drugs Res Dev . 2004;5:155–159
  146. Vasey PA . Survival and longer-term toxicity results of the SCOTROC study (Docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC)) . Proc Am Soc Clin Oncol . 2002;21:202a; (abstr 804)
  147. Guastalla JP , Dieras V . The taxanes (Toxicity and quality of life considerations in advanced ovarian cancer) . Br J Cancer . 2003;89(suppl 3):S16–S22
  148. Vasey PA . Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer . J Clin Oncol . 2003;21(suppl):136–144
  149. Schiller JH , Harrington D , Belani CP , et al.   Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med . 2002;346:92–98
  150. Trobaugh-Lotrario AD , Smith AA , Odom LF . Vincristine neurotoxicity in the presence of hereditary neuropathy . Med Pediatr Oncol . 2003;40:39–43
  151. Vinorelbine Tartrate Package Insert . Irvine, CA: Gensia Sicor Pharmaceuticals, Inc; 2002;
  152. Tosi P , Zamagni E , Cellini C , et al.   Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma . Eur J Haematol . 2005;74:212–216
  153. Offidani M , Corvatti L , Marconi M , et al.   Common and rare side-effects of low-dose thalidomide in multiple myeloma (focus on the dose-minimizing peripheral neuropathy) . Eur J Haematol . 2004;72:403–409
  154. Cytarabine . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 965
  155. Osborne WL , Holyoake TL , McQuaker IG , et al.   Fatal peripheral neuropathy following FLA chemotherapy . Clin Lab Haematol . 2004;26:295–296
  156. Etoposide . In: American Hospital Formulary Service (AHFS) . Bethesda, MD: American Society of Health-System Pharmacists (ASHP); 2002;p. 1001
  157. Roferon . Drug Package Insert . Nutley, NJ: Hoffman-LaRoche; 2003; September
  158. Postma TJ , Heimans JJ , Muller MJ , et al.   Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy . Ann Oncol . 1998;9:739–744
  159. Guidance for the Industry Providing Evidence of Effectiveness for Human Drug and Biology Products . Washington, DC: FDA, US Department of Health and Human Services; 1998;
  160. Guidance for the Industry E9 Statistical Principles for Clinical Trials . Washington, DC: FDA, US Department of Health and Human Services; 1998;
  161. United States Code of Federal Regulations, Title 21, Part 314
  162. Leidy NK , Revicki DA , Geneste B . Recommendations for evaluating the validity of quality of life claims for labeling and promotion . Value Health . 1999;2:113–127
  163. Chassany O , Sagnier P , Marquis P , et al.   Patient-reported outcomes (The example of health related quality of life a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process) . Drug Inf J . 2002;36:209–238
  164. Lohr KN , Aaronson NK , Alonso J , et al.   Evaluating quality-of-life and health status instruments (Development of scientific review criteria) . Clin Ther . 1996;18:979–992
  165. Galer BS , Jensen MP . Development and preliminary validation of a pain measure specific to neuropathic pain (The neuropathic pain scale) . Neurology . 1997;48:332–338
  166. Au E , Loprinzi CL , Dhodapkar M , et al.   Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity . J Clin Oncol . 1994;12:2751–2755
  167. Dellon AL . The vibrometer . Plast Reconstr Surg . 1983;71:427–431
  168. Shy ME , Frohman EM , So YT , et al.   Quantitative sensory testing (Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology) . Neurology . 2003;60:898–904
  169. Elderson A , Gerritsen van der Hoop R , Haanstra W , et al.   Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity . J Neurol Sci . 1989;93:167–174
  170. Kamon N . Quantitative measurement of vibratory perception threshold using a new vibrometer TM-31A . J Occup Med . 1994;36:989–996
  171. Oshita F , Saijo N , Shinkai T , et al.   Correlation between total dose of cisplatin and vibratory perception threshold in chemotherapy induced neuropathy of cancer patients . Cancer J . 1992;5:165–169
  172. Mayerhofer K , Bodner-Adler B , Bodner K , et al.   Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer (Efficacy and adverse effects with special consideration of peripheral neurotoxicity) . Anticancer Res . 2000;20:4047–4050
  173. Apfel SC , Kessler JA , Adornato BT , et al.  NGF Study Group   Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy . Neurology . 1998;51:695–702
  174. Van Deursen RW , Sanchez MM , Derr JA , et al.   Vibration perception threshold testing in patients with diabetic neuropathy (Ceiling effects and reliability) . Diabet Med . 2001;18:469–475
  175. Tunis S , Shuren J , Fernandez MJ . Medicare coverage Policy ∼NCDs, electrodiagnostic sensory nerve conduction threshold . 2002; Administrative File CAG-00106N
  176. Calhoun E , Fishman D , Roland P , et al.   Validity and selective sensitivity of the FACT/GOG-Ntx . Proc Am Soc Clin Oncol . 2000;19:446a; (abstr 1751)
  177. Calhoun EA , Welshman EE , Chang CH , et al.   Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy . Int J Gynecol Cancer . 2003;13:741–748
  178. Cella D , Peterman A , Hudgens S , et al.   Measuring the side effects of taxane therapy in oncology (The Functional Assessment of Cancer Therapy-Taxane (FACT-taxane)) . Cancer . 2003;98:822–831
  179. Epstein AM , Hall JA , Tognetti J , et al.   Using proxies to evaluate quality of life. Can they provide valid information about patients’ health status and satisfaction with medical care? . Med Care . 1989;27(suppl):S91–S98
  180. Grossman SA , Sheidler VR , Swedeen K , et al.   Correlation of patient and caregiver ratings of cancer pain . J Pain Symptom Manage . 1991;6:53–57
  181. Calhoun EA , Fishman DA , Roland PY , et al.   Total cost of chemotherapy-induced hematologic and neurologic toxicity . Proc Am Soc Clin Oncol . 1999;18a:1606; (abstr 886)
  182. Calhoun EA , Chang CH , Welshman EE , et al.   Evaluating the total costs of chemotherapy-induced toxicity (results from a pilot study with ovarian cancer patients) . Oncologist . 2001;6:441–445
  183. Gandara DR , Perez EA , Weibe V , et al.   Cisplatin chemoprotection and rescue (pharmacologic modulation of toxicity) . Semin Oncol . 1991;18(suppl 3):49–55
  184. Hausheer FH , Kochat H , Parker AR , et al.   New approaches to drug discovery and development (A mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent) . Cancer Chemother Pharmacol . 2003;52(suppl):S3–S15
  185. Windebank AJ , Smith AG , Russell JW . The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro . Neurology . 1994;44:488–494
  186. Hayakaawa K , Itoh T , Niwa H , et al.   NGF prevention of neurotoxicity induced by cisplatin, vincristine and Taxol depends on toxicity of each drug and NGF treatment schedule (In vitro study of adult rat sympathetic ganglion explants) . Brain Res . 1998;794:313–319
  187. Apfel SC , Arezzo JC , Lipson L , et al.   Nerve growth factor prevents experimental cisplatin neuropathy . Ann Neurol . 1992;31:76–80
  188. Apfel SC , Schwartz S , Bruce T , et al.   Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy . JAMA . 2000;284:2215–2221
  189. Müller LJ . Morphological and electrophysiological study of the effects of cisplatin and ORG 2766 on rat spinal ganglion neurons . Cancer Res . 1990;50:2437–2442
  190. Roberts JA , et al.   A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer . Gynecol Oncol . 1997;67:172–177
  191. van der Hoop RG , Vecht CJ , van der Burg ME , et al.   An ACTH- (4-9) analog prevents cisplatin-induced neuropathy in ovarian cancer patients . N Engl J Med . 1990;322:89–94
  192. Hovestadt A , van der Burg ME , Verbiest HB , et al.   The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo . J Neurol . 1992;239:143–146
  193. Apfel SC . Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors . Cancer Invest . 2000;18:564–573
  194. Hensley ML , Schuchter LM , Lindley C , et al.   American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants . J Clin Oncol . 1999;17:3333–3355
  195. Gelmon K , Eisenhauer E , Bryce C , et al.   Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer . J Clin Oncol . 1999;17:3038–3047
  196. Moore DH , Donnelly J , McGuire WP , et al.   Limited access trial using amifostine for protection against cisplatin- and paclitaxel-induced neurotoxicity (A phase II study of the Gynecologic Oncology Group) . J Clin Oncol . 2003;21:4207–4213
  197. Leong SS , Tan EH , Fong KW , et al.   Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer . J Clin Oncol . 2003;21:1767–1774
  198. Gradishar WJ , Stephenson P , Glover DJ , et al.   A phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma (An Eastern Cooperative Group study (E8188)) . Cancer . 2001;92:2517–2522
  199. Makino H . Treatment and care of neurotoxicity from taxane anticancer agents . Br J Cancer . 2004;11:100–104
  200. Cascinu S , Graziano F , Del Ferro E , et al.   Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma . Cancer . 1998;83:1917–1922
  201. Anderson ME , Naganuma A , Meister A . Protection against cisplatin toxicity by administration of glutathione ester . FASEB J . 1990;4:3251–3255
  202. Leone R , Fracasso ME , Soresi E , et al.   Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin . Cancer Chemother Pharmacol . 1992;29:385–390
  203. Zunino F , Pratesi G , Micheloni A , et al.   Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug . Chem Biol Interact . 1989;70:89–101
  204. Aebi S , Assereto R , Lauterburg BH . High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine . Eur J Clin Invest . 1991;21:103–110
  205. Hamers FP , Brakkee JH , Cavalletti E , et al.   Reduced glutathione protects against cisplatin-induced neurotoxicity in rats . Cancer Res . 1993;53:544–549
  206. Tognella S . Pharmacological interventions to reduce platinum-induced toxicity . Cancer Treat Rev . 1990;17:139–142
  207. Oriana S , Bohm S , Spatti G , et al.   A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity . Tumori . 1987;73:337–340
  208. Pirovano C , Balzarini A , Bohm S , et al.   Peripheral neurotoxicity following high-dose cisplatin with glutathione (clinical and neurophysiological assessment) . Tumori . 1992;78:253–257
  209. Bernstein EF , Pass HA , Glass J . Modulation of cisplatin toxicity by glutathione . Int J Oncol . 1995;7:353–358
  210. Bogliun G , Marzorati L , Marzola M , et al.   Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer . Int J Gynecol Cancer . 1996;6:415–419
  211. Bohm S , Battista Spatti G , Di Re F , et al.   A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma . Anticancer Res . 1991;11:1613–1616
  212. Cascinu S , Labianca R , Alessandroni P , et al.   Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim (A report from the Italian Group for the Study of Digestive Tract Cancer) . J Clin Oncol . 1997;15:3313–3319
  213. Cascinu S , Catalano V , Cordella L , et al.   Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer (A randomized, double-blind, placebo-controlled trial) . J Clin Oncol . 2002;20:3478–3483
  214. Cozzaglio L , Doci R , Colella G , et al.   A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer . Tumori . 1990;76:590–594
  215. Romero FJ , Roma J . Glutathione and protein kinase C in peripheral nervous tissue . Methods Enzymol . 1995;252:146–153
  216. Parnis FX , Coleman RE , Harper PG , et al.   A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer . Eur J Cancer . 1995;31A:1721
  217. Smyth JF , Bowman A , Perren T , et al.   Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin (Results of a double-blind, randomised trial) . Ann Oncol . 1997;8:569–573
  218. Tedeschi M , De Cesare A , Oriana S , et al.   The role of glutathione in combination with cisplatin in the treatment of ovarian cancer . Cancer Treat Rev . 1991;18:253–259
  219. Vahdat L , Papadopoulos K , Lange D , et al.   Reduction of paclitaxel-induced peripheral neuropathy with glutamine . Clin Cancer Res . 2001;7:1192–1197
  220. Vahdat L . Reduction of paclitaxel induced peripheral neuropathy with glutamine . Chemotherapy Foundation Symposium XVIII Innovative Cancer Therapy for Tomorrow . 2000; New York, NY, November 8-11, (abstr 1590)
  221. Vardimon L . Neuroprotection by glutamine synthetase . Isr Med Assoc J . 2000;2(suppl):46–51
  222. Boyle FM , Wheeler HR , Shenfield GM . Glutamate ameliorates experimental vincristine neuropathy . J Pharmacol Exp Ther . 1996;279:410–415
  223. Boyle FM , Wheeler HR , Shenfield GM . Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate . J Neurooncol . 1999;41:107–116
  224. Wong GY , Michalak JC , Sloan JA , et al.   A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy (A North Central Cancer Treatment Group study) . J Clin Oncol . 2005;23:729s; (abstr 8001)
  225. Mitchell P , Goldstein D , Michael M , et al.   White addition of gabapentin to a modified FOLFOX regimen does not reduce neurotoxicity in patients with advanced colorectal cancer . J Clin Oncol . 2005;23:266s; (abstr 3581)
  226. Adelsberger H , Quasthoff S , Grosskreutz J , et al.   The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons . Eur J Pharmacol . 2000;406:25–32
  227. Wilson RH , Lehky T , Thomas RR , et al.   Acute oxaliplatin-induced peripheral nerve hyperexcitability . J Clin Oncol . 2002;20:1767–1774
  228. Lersch C , Schmelz R , Eckel F , et al.   Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer . Clin Colorectal Cancer . 2002;2:54–58
  229. Hausheer FH , Kanter P , Cao S , et al.   Modulation of platinum induced toxicities and therapeutic index (Mechanistic insights and first and second-generation protecting agents) . Semin Oncol . 1998;25:584–599
  230. Hausheer F , Cavaletti G , Tredici G , et al.   Oral and intravenous BNP7787 protects against platinum neurotoxicity without in vitro or in vivo tumor protection . Proc Am Assoc Cancer Res . 1999;40:398; (abstr 2633)
  231. Cavalletti E , Cavaletti G , Tredici G , et al.   Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats . Proc Am Assoc Cancer Res . 1999;40:398; (abstr 2632)
  232. Boven E , Verschraagen M , Hulscher TM , et al.   BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts . Eur J Cancer . 2002;38:1148–1156
  233. Schilsky R , Schwartz G , Berghorn E , et al.   Phase I trial of escalating doses of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (Tax) . Proc Am Soc Clin Oncol . 1999;18:169a; (abstr 647)
  234. Boven E , Westerman M , van Groeningen CJ , et al.   Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule . Br J Cancer . 2005;92:1636–1643
  235. Takeda K , Negoro S , Matsui K , et al.   Phase I Safety and pharmacokinetic trial of BNP7787 in patients receiving cisplatin (CDDP) and paclitaxel (PTX) for advanced non-small cell lung cancer (NSCLC). An Osaka Phase I Study Group trial . Proc Am Soc Clin Oncol . 2002;19:114a; (abstr 453)

PII: S0093-7754(05)00493-8

doi: 10.1053/j.seminoncol.2005.12.010

Seminars in Oncology
Volume 33, Issue 1 , Pages 15-49 , February 2006

Article Tools

* Image Usage & Resolution